A Randomized, Open-label, Dose-ranging Study of Oral Delayed Release Prednisone in Patients With Untreated Polymyalgia Rheumatic (PMR)

Trial Profile

A Randomized, Open-label, Dose-ranging Study of Oral Delayed Release Prednisone in Patients With Untreated Polymyalgia Rheumatic (PMR)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 May 2017

At a glance

  • Drugs Prednisone (Primary)
  • Indications Polymyalgia rheumatica
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2017 The phase has been from Phase 4 to phase 2.
    • 01 May 2017 Status changed from recruiting to discontinued.
    • 15 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top